BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/11/2026 6:12:01 AM | Browse: 3 | Download: 1
 |
Received |
|
2026-01-13 03:34 |
|
Peer-Review Started |
|
2026-01-13 03:34 |
|
First Decision by Editorial Office Director |
|
2026-01-21 09:33 |
|
Return for Revision |
|
2026-01-21 09:33 |
|
Revised |
|
2026-01-27 06:43 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-02-28 02:32 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-02-28 04:42 |
|
Articles in Press |
|
2026-02-28 04:42 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-07-31 06:41 |
|
Publish the Manuscript Online |
|
2026-08-11 06:12 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Correspondence |
| Article Title |
Letter to the Editor: Lysosomal vulnerability as a therapeutic axis for overcoming proteasome inhibitor resistance in gastric cancer
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Wen-Wen Liu and Xiao-Jun Yang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Natural Science Foundation of Gansu Province |
No. 25JRRA304 |
| Doctoral Fund of the Key Laboratory of Gastrointestinal Tumor Diagnosis and Treatment of the National Health Commission |
No. NHCDP2022001 |
| the Doctoral Supervisor Cultivation Program of Gansu Provincial Hospital |
No. 22GSSYA-3 |
|
| Corresponding Author |
Xiao-Jun Yang, MD, PhD, Professor, Department of General Surgery, Gansu Provincial Hospital, No. 199 Donggang West Road, Chengguan District, Lanzhou 730000, Gansu Province, China. yangxjmd@aliyun.com |
| Key Words |
Lysosomal vulnerability; Proteasome inhibitor resistance; Bortezomib; Gastric cancer; Transcription factor EB; Patient-derived organoids |
| Core Tip |
Proteasome inhibitor resistance in solid tumors remains a major therapeutic challenge. This letter highlights lysosomal vulnerability as a central adaptive mechanism underlying bortezomib resistance in gastric cancer. By reframing lysosomes as active regulators of proteotoxic stress and drug sequestration rather than passive degradative organelles, the discussed study supports lysosome-targeted strategies as a promising therapeutic axis. Patient-derived organoid validation further underscores the translational relevance of intercepting lysosome-centered stress adaptation to enhance proteasome inhibitor efficacy. |
| Publish Date |
2026-08-11 06:12 |
| Citation |
Liu WW, Yang XJ. Letter to the Editor: Lysosomal vulnerability as a therapeutic axis for overcoming proteasome inhibitor resistance in gastric cancer. World J Gastroenterol 2026; 32(33): 118835
|
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i33/118835.htm |
| DOI |
https://doi.org/10.3748/wjg.118835 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
